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Structural
The timing of intervention in aortic stenosis (AS) is crucial. It is evident that 
severe AS is associated with poor survival when left untreated.1 Although 
current guidelines recommend aortic valve replacement (AVR) in patients 
with symptomatic severe AS or evidence of left ventricular dysfunction 
(left ventricular ejection fraction [LVEF] <50%), there is growing evidence 
that this treatment paradigm may lead to intervention after significant 
cardiac damage has occurred, with resultant poorer outcomes.2–4 Some 
patients with symptoms of decompensation (breathlessness, chest pain 
or syncope) only have moderate AS, yet have no other pathologies to 
which their symptoms can be attributed. 
AVR may be considered in patients with moderate AS who are undergoing 
surgery for other indications.2,3 Current guidelines suggest that patients with 
moderate AS (defined as peak transaortic velocity of 3.0–3.9 m/s or mean 
gradient [MG] of 20–39 mmHg) should undergo surveillance yearly, and AVR 
deferred until the AS becomes severe. Transcatheter aortic valve 
replacement (TAVR) is currently not indicated in moderate disease. However, 
there are no established recommendations for the treatment of moderate 
AS with left ventricular systolic dysfunction, despite growing evidence of 
morbidity and mortality in this population.5 As with most guideline 
recommendations in valvular heart disease, there is a lack of randomised 
control trial data to support or refute earlier intervention in these patients. 
The Biology of Aortic Stenosis
It is recognised that AS is not only a disease of the valve but also of the 
myocardium.6 Longstanding AS causes an increase in afterload, which 
leads to a myocardial remodelling response. This initial adaptive process 
eventually becomes maladaptive, and determines disease progression, 
symptoms and outcomes. The left ventricular response to AS is complex 
and consists of a combination of wall thickening, concentric remodelling 
and change in cavity size to maintain wall stress. In the later maladaptive 
stages, capillary rarefaction and cell death occur, as well as focal and 
diffuse myocardial fibrosis. How and when these processes develop is 
poorly understood, although sex differences appear particularly 
important.7 The afterload response conferred by the vasculature is 
important and varies between individuals. The prevalence of 
atherosclerosis and hypertension is also high in these patients, which can 
accelerate arterial stiffness.
AS – conventionally defined in binary terms (moderate or severe) – is 
better characterised by a number of relatively distinct phenotypes and 
how these relate to clinical courses/outcomes. Because conventional 
high gradient does not develop in many cases, pathological changes 
must be occurring at an earlier point in the disease process in some, if not 
all individuals. This is supported by the strong signal of symptom limitation 
at the moderate severity.
The Progression of Aortic Stenosis
The natural history of severe, symptomatic AS has been extensively 
documented.8–9 However, there is much less information on clinical 
outcomes in adults with moderate AS and the existing literature is 
heterogeneous. It is important to differentiate the anatomical progression 
Abstract
Current guidelines recommend aortic valve replacement in patients with severe aortic stenosis in the presence of symptoms or a left ventricular 
ejection fraction <50%. However, patients with less than severe aortic stenosis may also experience symptoms and recent literature suggests 
that the prognosis is not as benign as previously reported. There are no recommendations for patients with moderate aortic stenosis and left 
ventricular dysfunction, despite the high associated morbidity and mortality. There is also some evidence that these patients may benefit from 
early aortic valve intervention. It is recognised that aortic stenosis not only affects the valve but also has a complex myocardial response. This 
review discusses the natural history of moderate aortic stenosis along with the role of multimodality imaging in risk stratification in these patients.
Keywords
Aortic stenosis, biology, progression, echocardiography, imaging, interventions, outcomes
Disclosure: GL is supported by research and program grants by Medtronic and holds research and speaking grants by Edwards Lifesciences. TAT is funded by a British 
Heart Foundation Intermediate Research Fellowship (FS/19/35/35374), and indirectly supported by the University College London Hospitals and Barts NIHR Biomedical 
Research Centres. All other authors have no conflicts of interest to declare.
Received: 29 January 2021 Accepted: 29 March 2021 Citation: Interventional Cardiology Review 2021;16:e09. DOI: https://doi.org/10.15420/icr.2021.04 
Correspondence: Guy Lloyd, Heart Valve Clinic and Echocardiography Laboratory, Barts Heart Centre, St Bartholomew’s Hospital, West Smithfield, London, EC1A 7BE, UK. 
E: guy.lloyd1@nhs.net
Open Access: This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial 
purposes, provided the original work is cited correctly.
Moderate Aortic Stenosis: What is it and When Should We Intervene?
Sveeta Badiani ,1,2 Sanjeev Bhattacharyya ,1,2,3 Nikoo Aziminia ,1 Thomas A Treibel 1,3 and Guy Lloyd 1,2,3
1. Heart Valve Clinic and Echocardiography Laboratory, Barts Heart Centre, St Bartholomew’s Hospital, London, UK; 
2. William Harvey Research Institute, Queen Mary University of London, UK; 
3. Institute of Cardiovascular Sciences, University College London, London, UK
Moderate Aortic Stenosis: What is it and When Should We Intervene?
INTERVENTIONAL CARDIOLOGY REVIEW
Access at: www.ICRjournal.com
of stenosis (‘how narrow?’) and the clinical progression with adverse 
outcome (‘how bad?’). 
Anatomical Progression
There is a wide range in the progression rate, and it is unclear why some 
patients have a rapid disease progression and some do not. 
Haemodynamic AS progression is classically considered as constant and 
homogeneous (average increase in peak velocity by 0.3 m/s per year and 
an increase in MG by 7 mmHg per year) but is highly variable among 
individuals. As yet, no medical therapies have proven effective in reducing 
progression of AS or improving clinical outcomes.10
Clinical Progression
Earlier studies based on patient groups identified at cardiac catheterisation 
suggested a relatively benign prognosis in patients with moderate AS.11,12 
Horstkotte et al. demonstrated a time interval between the first 
manifestation of moderate AS and progression to severe stenosis 
requiring surgery of 13.4 years.12 
Later studies suggest that both clinical outcomes and progression to 
severe AS occur at a very high rate.13–20 Comparison of outcomes in 
patients with moderate AS is difficult because of the marked differences 
between studies (differences in symptom status, definition of stenosis 
severity and modality used to assess AS, study design, choice of end-
points and definition of event-free survival). Nevertheless, moderate AS is 
associated with a substantial increase in mortality from both cardiac and 
non-cardiac causes. Furthermore, progression to severe disease can 
occur much more rapidly than previously expected. 
The studies also identify characteristics (e.g. moderate or severe aortic 
valve calcification and concomitant coronary artery disease) that may put 
certain patients at risk for more rapid progression of AS.21 Data from the 
Heart Valve Clinic International Database registry showed that in patients 
with moderate AS at baseline, independent determinants of cardiovascular 
mortality were dyslipidaemia and peak velocity. There was also a trend for 
association between cardiovascular mortality and LVEF.22 
Observational data from a large Australian registry sought to determine 
more definitively the prognostic impact of increasing severity of AS. 
Echocardiographic findings from 3,315 patients with moderate AS were 
linked to long-term mortality. The 5-year mortality was 56%, after adjusting 
for age, sex, left ventricular systolic or diastolic dysfunction and aortic 
regurgitation. The risk of dying in the longer term was similar to the risk in 
patients presenting with severe AS at baseline.5 In the population-based 
study by Livanainen et al., moderate AS was associated with an increased 
risk of all cause and cardiovascular mortality; however the independent 
predictive value was lost when left ventricular mass and systolic function 
were included in the analysis.14 The studies detailing clinical outcomes in 
patients with moderate AS are presented in Table 1.
It is also important to note that patients with moderate mixed aortic valve 
disease (AS and regurgitation) are at risk for all-cause mortality, and that 
AVR significantly reduced this risk, independent for aortic valve area 
(AVA), symptom status and after controlling for confounding variables.23 
Aortic Stenosis and Left Ventricular Dysfunction
Left ventricular dysfunction has been reported in a quarter of patients with 
AS.24 The natural progression of AS comprises different phenotypic 
presentations involving patients who will develop left ventricular 
dysfunction and symptoms early, much before reaching the limit definition 
of severe AS. Both AS severity and left ventricular dysfunction are 
variables with definitions of ‘severe’ and ‘abnormal’ based on 
observational clinical studies.25,26 However, there is some evidence to 
suggest that patients with conventionally defined moderate AS and heart 
failure may benefit from AVR.27–29 
The study by van Gils et al. showed that 61% of patients with moderate AS 
and left ventricular systolic dysfunction died, underwent AVR or were 
hospitalised for heart failure, at 4-year follow-up with male sex, New york 
Heart Association Class III or IV, and higher peak aortic velocities 
independently predicting events.26 A retrospective analysis from the Duke 
Echocardiographic database reported a mortality benefit associated with 
AVR (with or without concomitant coronary artery bypass grafting) for 
moderate AS and left ventricular systolic dysfunction (LVSD), compared 
with medical management.28 These findings differ from those of Fougeres 
et al., who found that in patients with pseudo-severe (moderate) AS, there 
was no difference in the survival rate compared to controls with LVSD and 
no valve disease.29
Data from Hayward et al. identified 169 patients with moderate AS and left 
ventricular impairment (AVA 1–1.5 cm2 and LVEF <50%) and sought to 
identify determinants of outcomes. The primary endpoint was all cause 
mortality with a median follow-up period of 22.9 months. Patients with 
abnormal global longitudinal strain (GLS) had significantly worse survival 
and the only independent predictor of outcome was GLS.30 A recently 
published study by Ito et al. showed that in patients with moderate AS, 
those with decreased LVEF and/or indexed stroke volume were at 
increased risk of mortality.31
Evidence for Benefit from Earlier Intervention
In patients with symptomatic AS (AVA <1 cm2) who had a low gradient and 
normal flow (NFLG), intervention was associated with reduced cardiac-
related mortality, as opposed to conservative treatment.32 Long-term data 
are equivocal. These findings are similar to another study that demonstrated 
a similar long-term mortality when comparing NFLG patients with patients 
with moderate AS.33 In contrast, another study found a similar survival in 
patients undergoing early AVR compared with watchful waiting .34 
Moon et al. reported that among 255 patients with moderate AS and 
concomitant LVSD, 47.5% of patients died and 18.8% received AVR during 
a median of 1.8 years of follow-up. The incidence of all cause death was 
significantly lower in the early AVR group compared with the medical 
treatment group. The LVEF also improved to >50% in 59.5% of the early 
AVR group. Limitations include the single-centre nature and small 
patient numbers.35 
The investigators of the TAVR-UNLOAD trial aim to provide further insight 
into moderate AS with left ventricular dysfunction. Three hundred patients 
will be randomised into two arms: TAVR combined with optimised heart 
failure therapy versus optimal heart failure therapy alone. The primary 
endpoint will be a composite of all-cause death, disabling stroke, heart 
failure hospitalisations, symptomatic aortic valve disease or non-disabling 
stroke.36 
Hypertension and concurrent coronary artery disease are common in 
patients with AS. Hypertension may also be a risk factor for AS and adds 
to the total pressure load on the left ventricle. Medical therapy for 
hypertension follows standard guidelines, starting at a low dose and 
titrating upwards as needed to achieve blood pressure control. All 
patients should be screened and treated for hypercholesterolaemia.3 
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The current data have important clinical implications. Whether they 
support AVR in patients with moderate AS before progression to severe is 
open to debate. However, it is important to question the conventional 
guidelines of expectantly managing these patients, suggesting that they 
require much closer follow-up and more aggressive management than 
the present guidelines indicate. 
The Role of Multi-modality Imaging
Echocardiography
Echocardiographic evaluation starts with a visual assessment of the 
structure, calcification and mobility of the valve. AS severity is 
conventionally graded by peak velocity, MG and AVA (Figure 1). The 
classification of AS severity is not always straightforward, and 
echocardiographic findings are discordant in one in three patients.37 A 
distinction needs to be made between those with low flow (<35 ml/m2), 
and those with normal flow, in whom measurement inaccuracy or the 
discordance between a MG of 40 mmHg and a valve area of 1.0 cm2 are 
the more likely explanations. Additional investigations may be required. In 
patients with a reduced LVEF, low gradient and low AVA, dobutamine 
stress echocardiography may help in differentiating patients with true 
severe AS from pseudo-severe (moderate) AS.38 
A decrease in flow may be because of an increase in global left ventricular 
afterload not only as a result of the valvular stenosis but also from a 
Table 1: Studies of Clinical Outcomes in Moderate Aortic Stenosis








Turina et al. 198711 Retrospective AVA 0.95–1.4 cm2 on cardiac 
catheterisation
No coronary artery disease
30 43 33 6.6 years 100% at 1 year
80% at 4 years
Horstkotte et al. 198812 Retrospective AVA 0.8–1.5 cm2 236 39 ± 18 rheumatic AS
48 ± 6 bicuspid AS
66 ± 12 degenerative 
NR Average time interval 
between the 
manifestation of 
moderate AS and 
surgery was 13.4 years
80% at 10 years
Kennedy et al. 199113 Retrospective AVA 0.7–1.2 cm2 on cardiac 
catheterisation
EF 55  ±  17%
66 67 ± 10 82 2.9 years 72% at 4 years
Livanainen et al. 199614 Prospective AVA 0.9–1.2 cm2
VTI ratio 0.36–0.44
26 75–86 NR 4 years Overall survival 50% at 
4 years
Overall survival without 
CV deaths 65% at 
4 years
Otto et al. 199715 Prospective Vmax 3–4 m/s 68 63 ± 16 0 2.5 ± 1.4 years 66% at 2 years
Rosenhek et al. 200416 Retrospective Vmax 2.5–3.9 m/s 176 58 ± 19 0 4 ± 1.6 years 70%  ±  4% at 3 years
Kearney et al. 201217 Prospective MG 25–40 mmHg
AVA 1.0–1.5 cm2
55 73 ± 6 0 6.5 ± 4.3 years 100% at 1 year
62% at 3 years
23% at 5 years
Mehrotra et al. 201818 Retrospective AVA 1.0–1.3 cm2 
LVEF >55%
81 79 19 3 years 80% at 3 years
Minners et al. 201319 Prospective Vmax 3–4 m/s 948 68  ±  9.7 NR 3.8 ± 1.2 years 95.7% at 1 year
68.5% at 3 years
49.1% at 5 years
Yechoor et al. 201320 Retrospective Vmax 3–4 m/s
MG 25–40 mmHg
AVA 1.0–1.5 cm2
EF 49 ± 12%
104 74  ±  10 NR 22 months 48% at 1 year
24% at 3 years
15% at 5 years
Delsalle et al. 201921 Prospective AVA 1.0–1.5 cm2 508 75 ± 11 13.6% NYHA III 
or IV
47 months 53% survival at 6 years
Lancellotti et al. 201822 Retrospective AVA 1.0–1.5cm2 514 68 ± 13 0 2.3 years 94% survival at 2 years
89% at 4 years
Van Gils et al. 201727 Retrospective Vmax 2–4 m/s
AVA 1.0–1.5 cm2 
LVEF <50%
305 73 ± 11 76%
34% NYHA III–IV
638 days (IQR 
280–1137)
39% at 4 years
Samad et al. 201628 Retrospective Vmax 3–4 m/s
MG 25–39 mmHg
AVA >1 cm2
1,090 75 (IQR 67–83) NR  5 years
Strange et al. 20195 Retrospective Vmax 3.0–3.9 m/s
MG 20.0–39.9 mmHg
AVA >1 cm2
3,315 74 ± 15 NR 1,208 days (IQR 
598–2,177)
21% mortality at 1 year
56% at 5 years
AS = aortic stenosis; AVA = aortic valve area; CV = cardiovascular; EF = ejection fraction; IQR = interquartile range; LVEF = left ventricular ejection fraction; MG = mean gradient; NR = not recorded; 
NYHA = New York Heart Association; VTI =  velocity time integral.
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decrease in systemic arterial compliance and/or increased vascular 
resistance.39 Assessment of the global left ventricular haemodynamic load 
by measuring the valvuloarterial impedance (Zva) has been shown to be 
superior to the standard measures of AS severity in predicting left 
ventricular dysfunction and clinical outcomes.40,41 Hachicha et al. have 
also demonstrated that Zva is a strong independent predictor of clinical 
outcome in patients with at least moderate AS.41 The left ventricle faces a 
double load; valvular and arterial, particularly in hypertension, which 
frequently co-exists in patients with AS. A high Zva may explain why a 
patient with moderate AS is symptomatic. It is currently unclear whether 
these patients should undergo aortic valve intervention in the presence of 
symptoms, even after aggressive blood pressure control. 
Assessment of the Left Ventricle
There is evidence to suggest that adaptive remodelling becomes 
maladaptive with increasing left ventricular hypertrophy and consequent 
myocardial fibrosis in patients with AS. Inappropriately high left ventricular 
mass (iLVM) is associated with increased mortality, AVR or hospital 
admission.42 iLVM is also common in asymptomatic mild-to-moderate AS 
and is associated with reduced left ventricular contractility.43 
Left ventricular impairment is a strong adverse prognostic marker and 
LVEF <50% even in asymptomatic patients is a Class I indication for AVR. 
However, LVEF may remain normal until later in the course of the disease. 
Systolic long axis function may be impaired, even in the presence of a 
normal ejection fraction, in patients with AS (Figure 1).44 
Asymptomatic patients with moderate AS have subclinical impaired 
systolic left ventricular function as measured by peak systolic tissue 
velocity (S’) and strain, compared to controls (S’ 4.1 ± 1.0 versus 4.8 ± 1.1 
cm/s; p<0.01 and strain −16.6 ± 2.7 versus −17.9± 2%; p<0.05). Septal E’ 
(early diastolic mitral annular velocity) was decreased and septal E/E’ was 
increased in the AS group compared with the controls.45 Patients with AS 
may also develop symptoms because of progressive diastolic dysfunction. 
A reduction in early diastolic mitral annular velocity (E’) and an increase in 
E/E’ were observed in patients with mild to moderate asymptomatic AS, 
and related to the severity of AS. These measures have been reported to 
correlate with left ventricular filling pressures and may be a useful 
predictor of developing symptoms.46 These findings demonstrate that the 
damage to the left ventricular myocardium is an on-going process, which 
starts long before the need for AVR according to the current guidelines. 
Impaired left ventricular GLS (LVGLS), as a potential surrogate of 
myocardial fibrosis, has been shown to be an independent predictor of 
mortality and adverse outcomes in both symptomatic and asymptomatic 
severe AS patients, suggesting that LVGLS is a better value for risk 
stratification and management of AS, than LVEF.47,48
It has been shown that clinical outcomes of patients with moderate AS are 
poor, highlighting the importance of detecting even mild degrees of left 
ventricular dysfunction before the AS becomes severe. Zhu et al. 
retrospectively analysed data from 287 patients with moderate AS (aortic 
valve peak velocity [AVVmax] 3.2 ± 0.5 m/s, MG 24.5 ± 7.4, AVA 1.26 ± 0.14 cm
2 
and LVEF 62 ± 6%). They found that mortality was significantly higher in 
patients with GLS ≥15.2% compared with GLS ≤15.2%. LVGLS was 
independently associated with survival even after adjusting for age, sex, 
coronary artery disease, LVEF, MG and symptomatic status.49 Increased 
afterload could possibly be already overwhelming even if AS is only 
moderate among patients with impaired GLS. Patients with impaired GLS 
had larger left ventricular mass index with concentric left ventricular 
hypertrophy and lower E velocities compared to those with preserved GLS.
Moderate AS based on current echocardiographic data may be associated 
with reduced survival, which in part may be related to comorbid clinical 
factors and co-existent cardiac abnormalities. Hence, the concept of staging 
AS and its relationship to clinical outcomes (rather than merely classifying 
the severity of the valve lesion based on echo criteria) may aid in the risk 
stratification of patients with AS. Genereux et al. characterised patients with 
symptomatic severe AS undergoing AVR into five stages: stage 0, no left 
ventricular damage; stage 1, left ventricular damage; stage 2, left atrial 
enlargement and mitral valve damage; stage 3, pulmonary hypertension 
and tricuspid damage; stage 4, right ventricular dysfunction has been 
proposed to aid the decision to potentially intervene in a more timely 
fashion. A main focus of these staging algorithms has been the changes that 
occur in the myocardium in AS and the pattern of left ventricular 
remodelling.50 Incorporation of LVGLS into the staging classification 
improves the prognostic value by identifying patients with more advanced 
cardiac damage.51
Including GLS (as a surrogate of myocardial fibrosis) in the 
echocardiographic evaluation of patients with AS, irrespective of its 
grade, may aid in the risk stratification of these patients. Early pressure 
unloading of the left ventricular can result in a more significant regression 
Transthoracic echocardiogram showing normal left ventricular dimensions (A) and a calcified aortic 
valve (B and C). Continuous wave Doppler trace shows peak aortic velocity 3.7 m/s and mean 
gradient 28 mmHg (D). Left ventricular ejection fraction is 62% (3D measurement; E) and impaired 
global longitudinal strain (F).
Figure 1: Transthoracic Echocardiogram of 
Patient With Moderate Aortic Stenosis
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of diffuse fibrosis. The limitations of the current evidence are its 
retrospective nature and single centre study design. There is a need for a 
randomised clinical trial to determine whether patients with moderate AS 
and impaired GLS benefit from earlier intervention. 
Exercise Echocardiography
Exercise stress echocardiography allows not just the assessment of 
functional capacity and haemodynamic changes, but also the 
measurement of trans-valvular gradient under higher flow conditions, 
measurement of left ventricular contractile function and estimation of 
pulmonary artery systolic pressures. Little is known about how the 
ventricle and vasculature respond to less than severe AS and whether this 
could lead to symptoms in susceptible individuals. More information may 
be revealed about the ventricle’s adaptation/maladaptation when placed 
under even mild stress compared to being at rest. 
Moderate AS is considered a pre-symptomatic stage although there is a 
strong suggestion that a proportion of patients are already symptomatic; 
up to 60% exhibited breathlessness on exertion in one study,52 and that 
these symptoms on exertion are more closely linked to outcome than 
resting echo based severity parameters. Changes in exercise performance 
in patients with moderate AS are not well understood although there is 
evidence to support a reduction in exercise time of around 5% over 2.5-
year follow-up.53 A small study of 38 apparently asymptomatic patients 
with moderate-to-severe AS revealed symptoms were associated with a 
lower peak VO2 on cardiopulmonary exercise testing, and lower peak 
stroke index during exercise. The limitation of the current evidence is that 
the cohorts either contain patients with both moderate and severe AS or 
have incomplete exercise data. Furthermore, the exercise data are 
confined to relatively crude treadmill parameters such as exercise time, 
but they do not establish the pathogenesis of the exercise limitation.
An abnormal left ventricular response to exercise (manifest by a lack of 
increment or decrease in LVEF on exercise) is associated with an increased 
likelihood of developing symptoms on exercise and lower survival free of 
cardiac events than those with an appropriate increase in LVEF on exercise. 
However, left ventricular longitudinal strain is a more powerful parameter 
than LVEF to predict the occurrence of symptoms, exercise tolerance and 
cardiac events. Huded et al., in a study of 504 asymptomatic patients with 
severe AS, showed that age and sex predicted metabolic equivalents (HR 
1.16), LVGLS and valvuloarterial impedance, offered incremental prognostic 
value.54 However, at present, no clinically applicable cut offs for contractile 
reserve using strain in AS have been validated. 
Exercise stress echocardiography using tissue Doppler imaging also 
provides prognostic information, in mild to moderate AS. A significant 
increase in the E/E’ ratio during exercise predicted adverse cardiac events, 
beyond exercise echocardiography or exercise testing alone.55 This 
highlights that the increased afterload alters the ventricular filling dynamics 
as well as the relaxing properties of the left ventricle in AS patients. The data 
demonstrates that objective assessment of the myocardium and valve 
behaviour under stress conditions, may aid in the decision making regarding 
aortic valve intervention, before irreversible myocardial changes occur.
Cardiopulmonary exercise testing provides an additional objective 
measure of exercise tolerance and has been shown to be feasible and 
reproducible in AS and able to identify a greater proportion of individuals 
with exercise intolerance than conventional parameters that are 
recommended in the current guidelines (symptoms or fall in blood 
pressure).56–58 Previous studies have shown that a significant proportion 
of patients with apparently asymptomatic moderate-to-severe AS exhibit 
a peak VO2 <84% predicted.
58,59 A reduced peak VO2 was associated with 
a lower event-free survival compared to a normal peak V02. No exercise 
stress echocardiography parameters however, were associated with 
peak V02, nor predicted event free survival.
59 Whether patients with 
purely moderate AS exhibit exercise limitation defined by a reduced V02 
peak is yet to be established.
Cardiac CT and PET
Quantification of aortic valve calcium (AVC) has been shown in multicentre 
studies to be reproducible and offers prognostic value above and beyond 
echocardiographic indices of AS severity (Figure 2).60,61 AVC load can be 
correlated with haemodynamic indicators of the severity of AS, as 
demonstrated by Boulif et al. in a study of 266 patients with moderate-
severe AS (defined by an effective orifice area of <1.5 cm2), thereby 
potentially providing a valuable surrogate marker of AS severity.62 AVC 
load may predict outcome, including in asymptomatic patients, 
independently of other markers that may be detected on echocardiography, 
such as AVA and EF. The possible distortion of the former by reduction of 
the latter, whereby reduced LVEF may impact on the AV gradient and 
thereby result in functionally low AVA, renders the use of independent 
markers of AS severity all the more crucial in order to plan interventions of 
the most appropriate means and timing.63–65 The inclusion of CT-AVC in 
guidelines for the assessment of AS severity provides the optimal 
framework with which to apply this marker to clinical practice.2 
A further interesting application of CT in AS is the use of hybrid PET-CT 
imaging to track both valvular inflammation and calcification with 
18F-flurodeoxyglucose and 18F-fluoride-PET-CT. Earlier studies have 
suggested that 18F-NaF activity predicts the rate of future disease 
progression as measured by CT-AVC and echocardiography and 
prospective studies are also underway to assess whether it can improve 
prediction of risk and response to therapy.65,66
Cardiac MRI
The importance of the transition from physiological adaptation to 
pathophysiological maladaptation in the myocardial remodelling response 
Figure 2: Cardiac CT for Aortic Valve Assessment
Leaflet aortic valve Agatston calcium score of 1095 AU in a patient with moderate aortic stenosis; 
the blooming artefact makes the calcium appear more prominent (A). Multi-planar reconstructions 
of the angiographic acquisition in the short axis of the tricuspid aortic valve (B, yellow) and the 
respective three chamber long axis (C, blue) and respective aortic cross-cut (D, red). 
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in AS was highlighted over 40 years ago in pivotal work by studying 
myocyte hypertrophy and fibrosis on myocardial histology. Work by 
Schwarz and others demonstrated proportional myocyte hypertrophy and 
diffuse interstitial fibrosis, as well as partly disease specific patterns of 
fibrosis, described as compact or ‘focal’, perimyseal, perivascular, 
plexiform or patchy.67 In AS, interfibre and perivascular fibrosis increase 
disproportionally.67 Later work also demonstrated gradients of fibrosis 
and capillary rarefaction from the subendocardium than in the 
subepicardium.68,69 Fast forward, we can now identify many of these 
changes non-invasively by cardiac MRI (CMR) using not only the superior 
accuracy of CMR to quantify left and right ventricular size, hypertrophy 
and function (Figure 3) but also quantifying both focal scar (with late 
gadolinium enhancement [LGE] imaging) and diffuse fibrosis (with T1 
mapping that allows the quantification of the extracellular volume fraction 
(ECV%). Both techniques have been validated against myocardial fibrosis 
on histology highlighting the previously described complex pattern of 
subendocardial microscars and mid-myocardial diffuse fibrosis.70–72 
Importantly, focal scar can already be detected in moderate AS. Everett et 
al. showed both the amount of LGE and elevation of ECV% increases in 
moderate AS prior to left ventricular impairment or symptom onset with 
new scar occurring both at the sites of existing LGE and, in a quarter of 
patients, at remote sites with the development of new areas of non-infarct 
LGE.73 Both LGE and ECV% are independent predictors of outcomes after 
AVR, but importantly LGE is irreversible, whereas diffuse fibrosis quantified 
by ECV% regresses after AVR.74–77 
Whether myocardial scar can be used to guide early AVR in asymptomatic 
severe AS, is currently under investigation in the EVOLVED study, which is 
the first multicentre randomised controlled trial to compare early AVR to 
routine care in asymptomatic severe AS guided by the presence of focal 
scar on LGE imaging.78 If this study provides a role of CMR in guiding 
timing of intervention, then the next conceivably are of CMR-guided early 
intervention will be moderate AS with evidence of myocardial 
decompensation (Figure 4). The increased use of CMR has also highlighted 
dual pathology AS and transthyretin-type cardiac amyloidosis, which 
occurs in one in eight elderly patients referred for TAVR.78,79 Although TAVR 
is beneficial in AS-amyloidosis, diagnosis is still important because new 
amyloid-directed pharmacotherapies are now available and should be 
considered. Beyond fibrosis and infiltration, CMR can also detect 
myocardial perfusion reserve and oedema, with studies on-going to 
establish the importance of microvascular perfusion and low grade of 
inflammation in the pathophysiological remodelling of AS.
Figure 3: Cardiac MRI in Aortic Stenosis
Valve and remodelling (A–E) and tissue characterisation (F-I). Short axis images of two patients with moderate AS. Patient one (F/H) has concentric left ventricular hypertrophy and evidence of 
non-infarct scarring; the LGE image (F) shows scarring of both papillary muscles as well as more subtle enhancement in the RV insertion points and subendocardially in the anterior and lateral wall; this 
is confirmed by elevated ECV of 35% in the same areas on the ECV map with a normal ECV of 26% in the remote myocardium (H). Patient two (G/I) has concentric LV hypertrophy; the LGE images shows 
diffuse, transmural late enhancement through the left ventricle with some enhancement of the right ventricle; the ECV map shows evidence of a globally severely elevated ECV of 50%, consistent with 
dual pathology of AS and cardiac amyloidosis. AS = aortic stenosis; ECV = extracellular volume fraction; LGE = late gadolinium enhancement; LV = left ventricle; RV = right ventricle.
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Just a Question of Classification?
The ultimate question is whether we need to re-classify AS bearing in 
mind the importance of the myocardial response and its impact on 
outcome, and the improved outcomes with better surgical and trans-
catheter technology (that lower the upfront risk and change the balance 
of risk-versus-benefit). While the label ‘severe’ signals the need for 
intervention, we should aim to describe the valvular insult to the 
myocardium and upstream cardiac structures as significant or non-
significant and then assess the resultant response.
How classification can have a counterproductive effect can be seen by 
the strict interpretation of the European Society of Cardiology (ESC) 
2017 guidelines that reclassified low-gradient severe AS to moderate 
AS unless presenting with low flow status (stroke volume index 
≤35 ml/m2) and high calcium scores (emphasising on mean pressure 
gradient and an integrated approach). Chan et al. demonstrated that 
strict adherence to 2017 ESC guidelines for valvular heart disease 
reclassified 45% of their severe asymptomatic severe AS cohort to 
moderate (PRIMID-AS) and that both the severe and reclassified groups 
had a higher risk compared with moderate AS with the reclassified 
group demonstrating an intermediate risk.80 This work from the 
PRIMID-AS investigators demonstrates that moderate AS clearly is in 
grey area where exercise testing, multimodality imaging, and possibly 
lower AS severity cut-offs may personalise the treatment of AS and 
may improve risk stratification.
Conclusion 
Moderate AS carries a high morbidity and mortality and there is evidence 
to suggest that these patients may benefit from earlier intervention. The 
current evidence highlights the importance of careful surveillance of 
these patients. However, small patient numbers and the retrospective 
study nature limit much of the evidence. Echocardiography is pivotal in 
guiding management, although alternative imaging modalities such as CT, 
CMR and PET are increasingly being used to assess disease activity and 
progression. A new era of randomised clinical trials is required to evaluate 
the hypothesis that imaging-driven care in earlier stage aortic valve 
disease with upstream intervention would result in better long-term 
clinical outcomes. 




















Concept figure illustrating Imaging parameters in the natural history of AS. AS = aortic stenosis; 
AVR = aortic valve replacement; LVEF = left ventricular ejection fraction; LVH = left ventricular 
hypertrophy. 
Clinical Perspective
• Aortic stenosis is the most common left-sided valve lesion 
requiring intervention and carries a substantial morbidity and 
mortality burden. 
• Clear guidelines exist for the management of patients with 
symptomatic severe aortic stenosis. 
• However, patients with moderate aortic stenosis may also 
experience symptoms, to which no other cause can be 
attributed to other than the valve. 
• It is well recognised that aortic stenosis is not only a disease of 
the valve, but also of the myocardium, and that a significant 
proportion of patients with moderate aortic stenosis will also 
have left ventricular dysfunction. 
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